SCHEMBL644569

SCHEMBL644569

COC(=O)c1ccc(C=O)c(OC)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.63
ERN1 O75460 5/20 0.58
KMT2A Q03164 2/20 0.56
ALDH1A1 P00352 5/20 0.56
MEN1 O00255 1/20 0.49
LMNA P02545 1/20 0.49
ATM Q13315 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HCRTR1 O43613 1/20 0.49
HCRTR2 O43614 1/20 0.49
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
CA12 O43570 1/20 0.49
CA7 P43166 1/20 0.49
XDH P47989 1/20 0.49
CA9 Q16790 1/20 0.49
CA14 Q9ULX7 1/20 0.49
KDM4E B2RXH2 1/20 0.48
TSHR P16473 1/20 0.48
TDP1 Q9NUW8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL310021 0.86 ERN1 (0.58) MAPTERN1KMT2AALDH1A1MEN1
SCHEMBL31084750 0.86 ERN1 (0.58) MAPTERN1KMT2AALDH1A1MEN1
SCHEMBL16533324 0.85 MAPT (0.61) MAPTERN1KMT2AALDH1A1MEN1
SCHEMBL21660344 0.85 ALDH1A1 (0.59) MAPTERN1KMT2AALDH1A1MEN1
SCHEMBL2961633 0.84 CA12 (0.65) ERN1ALDH1A1LMNACA1CA2
SCHEMBL23459305 0.84 MAPT (0.49) MAPTERN1KMT2AALDH1A1LMNA
SCHEMBL8992939 0.84 HSD17B2 (0.66) MAPTERN1KMT2AALDH1A1MEN1
SCHEMBL17747083 0.84 ALDH1A1 (0.58) MAPTERN1KMT2AALDH1A1MEN1
SCHEMBL25242944 0.83 ALDH1A1 (0.53) ALDH1A1CA1CA2
SCHEMBL8112678 0.83 MAPT (0.55) MAPTERN1KMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368667-A1 USP1 INHIBITOR SHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD (CN) 2025-12-04 US disclosed
EP-4582427-A1 USP1 INHIBITOR Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2025-07-09 EP disclosed
US-12258316-B2 Biphenyl compounds useful as muscarinic receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC (US) 2025-03-25 US disclosed
CN-119497713-A USP1 inhibitors 上海齐鲁制药研究中心有限公司 2025-02-21 CN disclosed
CN-118184658-A USP1 inhibitors 上海齐鲁制药研究中心有限公司 2024-06-14 CN disclosed
WO-2024046471-A9 USP1 INHIBITOR 上海齐鲁制药研究中心有限公司 2024-05-02 WO disclosed
CN-117776883-A Preparation method of aromatic ketone compound containing diaryl methane structure 湖南科技大学 2024-03-29 CN disclosed
WO-2024046471-A1 USP1 INHIBITOR 上海齐鲁制药研究中心有限公司 2024-03-07 WO disclosed
CN-114181061-B Preparation method of aromatic ketone compound containing diaryl methane structure 湖南科技大学 2024-01-23 CN disclosed
US-20220306579-A1 BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2022-09-29 US disclosed
WO-2000026197-A1 NOVEL INHIBITORS OF IMPDH ENZYME BRISTOL-MYERS SQUIBB COMPANY (US) 2000-05-11 WO disclosed
EP-0831891-A4 OXIDANT SCAVENGERS UNIV DUKE (US) 1999-02-03 EP disclosed
EP-0831891-A1 OXIDANT SCAVENGERS DUKE UNIVERSITY (US) 1998-04-01 EP disclosed
WO-1997005114-A1 QUINOLONE SULFONIMIDES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION LABORATORIOS MENARINI S.A. (ES) 1997-02-13 WO disclosed
WO-1996040223-A1 OXIDANT SCAVENGERS DUKE UNIVERSITY (US) 1996-12-19 WO disclosed
US-4753962-A HYPOGLYCEMIC, ANTIOBESITY AGENT BEECHAM GROUP P.L.C. (GB) 1988-06-28 US disclosed
US-4654371-A ANTI-OBESITY, HYPOGLYCEMIA AGENTS BEECHAM GROUP P.L.C. (GB) 1987-03-31 US disclosed
US-4478849-A HYPERGLYCEMIC AGENTS BEECHAM GROUP LIMITED (GB) 1984-10-23 US disclosed
EP-0006735-B1 SECONDARY AMINES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE BEECHAM GROUP PLC (GB) 1983-06-15 EP disclosed
EP-0006735-A1 Secondary amines, their preparation, pharmaceutical compositions containing them and their use BEECHAM GROUP PLC (GB) 1980-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306579-A1 BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS CHRM2, CHRM1, CHRM3 MAPT 4020/4885ERN1 3280/4885KMT2A 2049/4885
US-20250368667-A1 USP1 INHIBITOR USP1, USP2, USP28 MAPT 2468/4885ERN1 289/4885KMT2A 2034/4885
US-12258316-B2 Biphenyl compounds useful as muscarinic receptor antagonists CHRM2, CHRM1, CHRM3 MAPT 4020/4885ERN1 3280/4885KMT2A 2049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.